Magazine: The GLP-1 shortage is over. What’s next for compounders?
Pharmaceutical Technology
APRIL 30, 2025
The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisks semaglutide (Wegovy/Ozempic) and Eli Lillys tirzepatide (Mounjaro/Zepbound).
Let's personalize your content